Please enable JavaScript to continue using this application.

Compare $HALO vs $PCVX | Chartloom

Compare

$HALO vs $PCVX

Halozyme Therapeutics Inc · Vaxcyte Inc

HALO

Halozyme Therapeutics Inc

PCVX

Vaxcyte Inc

Compare $HALO vs $PCVX

Comparing Halozyme Therapeutics Inc and Vaxcyte Inc

HALOHalozyme Therapeutics Inc

PCVXVaxcyte Inc

HALOHalozyme Therapeutics Inc

Market cap

$13.10B

P/E (TTM)

32.36x

Forward P/E (NTM)

10.93x

Forward P/S (NTM)

6.32x

Rev growth (TTM)

41.2%

YTD performance

57.0%

52W performance

69.4%

FCF yield

4.0%

PCVXVaxcyte Inc

Market cap

$10.31B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

53.6%

52W performance

75.2%

FCF yield

-8.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

HALO

PCVX

Detailed metrics comparison

HALO

Halozyme Therapeutics Inc

PCVX

Vaxcyte Inc

Market Cap

HALO$13.10B

PCVX$10.31B

Enterprise Value

HALO$15.08B

PCVX$10.12B

Price

HALO$110.42

PCVX$71.38

P/E Ratio

HALO32.36x

PCVXN/A

P/S Ratio

HALO7.87x

PCVX0.00x

EV/Sales

HALO9.06x

PCVX0.00x

EV/EBITDA

HALO14.17x

PCVX0.00x

P/B Ratio

HALO86.87x

PCVX3.05x

P/FCF Ratio

HALO25.26x

PCVXN/A

EV/FCF

HALO29.09x

PCVX-10.99x

PEG Ratio

HALO1.08x

PCVXN/A

Forward P/E (NTM)

HALO10.93x

PCVXN/A

Forward P/S (NTM)

HALO6.32x

PCVXN/A

Revenue (TTM)

HALO$1.66B

PCVX$0

Revenue Growth (YoY)

HALO41.2%

PCVXN/A

Forward Rev Growth

HALO10.9%

PCVX157.2%

Gross Margin (TTM)

HALO82.4%

PCVX0.0%

Operating Margin (TTM)

HALO35.6%

PCVX0.0%

EBITDA Margin (TTM)

HALO63.7%

PCVX0.0%

Net Margin (TTM)

HALO24.9%

PCVX0.0%

FCF Margin (TTM)

HALO31.2%

PCVXN/A

Net Income (TTM)

HALO$414M

PCVX$-1.06B

FCF (TTM)

HALO$518M

PCVX$-921M

EPS (TTM)

HALO$3.41

PCVX-$7.37

ROE (TTM)

HALO180.6%

PCVX-3757.0%

ROA (TTM)

HALO16.6%

PCVX-3362.0%

ROIC (TTM)

HALO18.7%

PCVX-3757.0%

Cash

HALO$163M

PCVX$183M

Debt

HALO$2.15B

PCVX$0

Net Cash/Debt

HALO$-1.98B

PCVX$183M

Current Ratio (TTM)

HALO2.71x

PCVX5.72x

Quick Ratio (TTM)

HALO1.99x

PCVX5.48x

Debt/Equity (TTM)

HALO14.95x

PCVX0.00x

Debt/Assets (TTM)

HALO0.0%

PCVX0.0%

Interest Coverage (TTM)

HALON/A

PCVXN/A

Net Debt/EBITDA (TTM)

HALO0.00x

PCVX0.00x

Beta

HALO0.94

PCVX1.31

52W Performance

HALO69.4%

PCVX75.2%

YTD Performance

HALO57.0%

PCVX53.6%

% from 52W High

HALO-5.5%

PCVX-21.3%

% from 52W Low

HALO80.3%

PCVX79.0%

Asset Turnover (TTM)

HALO0.67x

PCVX0.00x

FCF Yield (TTM)

HALO4.0%

PCVX-8.9%

Earnings Yield (TTM)

HALO3.2%

PCVX-10.3%

Dividend Yield (TTM)

HALON/A

PCVXN/A

Rule of 40

HALO72.3

PCVX0.0

EV/GP/RG

HALO0.44

PCVXN/A

Ticker research

View HALO research View PCVX research

Metric	HALO Halozyme Therapeutics Inc	PCVX Vaxcyte Inc
Market & Valuation
Market Cap	$13.10B	$10.31B
Enterprise Value	$15.08B	$10.12B
Price	$110.42	$71.38
P/E Ratio	32.36x	N/A
P/S Ratio	7.87x	0.00x
EV/Sales	9.06x	0.00x
EV/EBITDA	14.17x	0.00x
P/B Ratio	86.87x	3.05x
P/FCF Ratio	25.26x	N/A
EV/FCF	29.09x	-10.99x
PEG Ratio	1.08x	N/A
Forward P/E (NTM)	10.93x	N/A
Forward P/S (NTM)	6.32x	N/A
Revenue & Growth
Revenue (TTM)	$1.66B	$0
Revenue Growth (YoY)	41.2%	N/A
Forward Rev Growth	10.9%	157.2%
Profitability
Gross Margin (TTM)	82.4%	0.0%
Operating Margin (TTM)	35.6%	0.0%
EBITDA Margin (TTM)	63.7%	0.0%
Net Margin (TTM)	24.9%	0.0%
FCF Margin (TTM)	31.2%	N/A
Net Income (TTM)	$414M	$-1.06B
FCF (TTM)	$518M	$-921M
EPS (TTM)	$3.41	-$7.37
ROE (TTM)	180.6%	-3757.0%
ROA (TTM)	16.6%	-3362.0%
ROIC (TTM)	18.7%	-3757.0%
Financial Health
Cash	$163M	$183M
Debt	$2.15B	$0
Net Cash/Debt	$-1.98B	$183M
Current Ratio (TTM)	2.71x	5.72x
Quick Ratio (TTM)	1.99x	5.48x
Debt/Equity (TTM)	14.95x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.94	1.31
52W Performance	69.4%	75.2%
YTD Performance	57.0%	53.6%
% from 52W High	-5.5%	-21.3%
% from 52W Low	80.3%	79.0%
Efficiency & Yields
Asset Turnover (TTM)	0.67x	0.00x
FCF Yield (TTM)	4.0%	-8.9%
Earnings Yield (TTM)	3.2%	-10.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	72.3	0.0
EV/GP/RG	0.44	N/A
Ticker research	View HALO research	View PCVX research

Valuation

P/E Ratio

HALO

32.36x

P/S Ratio

PCVX

0.00x

HALO

7.87x

EV/FCF

PCVX

-10.99x

HALO

29.09x

Growth & revenue

Revenue Growth TTM

HALO

41.2%

Forward Revenue Growth

PCVX

157.2%

HALO

10.9%

Profitability & performance

Gross Margin

HALO

82.4%

PCVX

0.0%

ROE

HALO

180.6%

PCVX

-3757.0%

FCF Yield %

HALO

4.0%

PCVX

-8.9%

52-Week Performance

PCVX

75.2%

HALO

69.4%

Detailed metrics comparison

HALO

Halozyme Therapeutics Inc

PCVX

Vaxcyte Inc

Market Cap

HALO$13.10B

PCVX$10.31B

Enterprise Value

HALO$15.08B

PCVX$10.12B

Price

HALO$110.42

PCVX$71.38

P/E Ratio

HALO32.36x

PCVXN/A

P/S Ratio

HALO7.87x

PCVX0.00x

EV/Sales

HALO9.06x

PCVX0.00x

EV/EBITDA

HALO14.17x

PCVX0.00x

P/B Ratio

HALO86.87x

PCVX3.05x

P/FCF Ratio

HALO25.26x

PCVXN/A

EV/FCF

HALO29.09x

PCVX-10.99x

PEG Ratio

HALO1.08x

PCVXN/A

Forward P/E (NTM)

HALO10.93x

PCVXN/A

Forward P/S (NTM)

HALO6.32x

PCVXN/A

Revenue (TTM)

HALO$1.66B

PCVX$0

Revenue Growth (YoY)

HALO41.2%

PCVXN/A

Forward Rev Growth

HALO10.9%

PCVX157.2%

Gross Margin (TTM)

HALO82.4%

PCVX0.0%

Operating Margin (TTM)

HALO35.6%

PCVX0.0%

EBITDA Margin (TTM)

HALO63.7%

PCVX0.0%

Net Margin (TTM)

HALO24.9%

PCVX0.0%

FCF Margin (TTM)

HALO31.2%

PCVXN/A

Net Income (TTM)

HALO$414M

PCVX$-1.06B

FCF (TTM)

HALO$518M

PCVX$-921M

EPS (TTM)

HALO$3.41

PCVX-$7.37

ROE (TTM)

HALO180.6%

PCVX-3757.0%

ROA (TTM)

HALO16.6%

PCVX-3362.0%

ROIC (TTM)

HALO18.7%

PCVX-3757.0%

Cash

HALO$163M

PCVX$183M

Debt

HALO$2.15B

PCVX$0

Net Cash/Debt

HALO$-1.98B

PCVX$183M

Current Ratio (TTM)

HALO2.71x

PCVX5.72x

Quick Ratio (TTM)

HALO1.99x

PCVX5.48x

Debt/Equity (TTM)

HALO14.95x

PCVX0.00x

Debt/Assets (TTM)

HALO0.0%

PCVX0.0%

Interest Coverage (TTM)

HALON/A

PCVXN/A

Net Debt/EBITDA (TTM)

HALO0.00x

PCVX0.00x

Beta

HALO0.94

PCVX1.31

52W Performance

HALO69.4%

PCVX75.2%

YTD Performance

HALO57.0%

PCVX53.6%

% from 52W High

HALO-5.5%

PCVX-21.3%

% from 52W Low

HALO80.3%

PCVX79.0%

Asset Turnover (TTM)

HALO0.67x

PCVX0.00x

FCF Yield (TTM)

HALO4.0%

PCVX-8.9%

Earnings Yield (TTM)

HALO3.2%

PCVX-10.3%

Dividend Yield (TTM)

HALON/A

PCVXN/A

Rule of 40

HALO72.3

PCVX0.0

EV/GP/RG

HALO0.44

PCVXN/A

Ticker research

View HALO research View PCVX research

Metric	HALO Halozyme Therapeutics Inc	PCVX Vaxcyte Inc
Market & Valuation
Market Cap	$13.10B	$10.31B
Enterprise Value	$15.08B	$10.12B
Price	$110.42	$71.38
P/E Ratio	32.36x	N/A
P/S Ratio	7.87x	0.00x
EV/Sales	9.06x	0.00x
EV/EBITDA	14.17x	0.00x
P/B Ratio	86.87x	3.05x
P/FCF Ratio	25.26x	N/A
EV/FCF	29.09x	-10.99x
PEG Ratio	1.08x	N/A
Forward P/E (NTM)	10.93x	N/A
Forward P/S (NTM)	6.32x	N/A
Revenue & Growth
Revenue (TTM)	$1.66B	$0
Revenue Growth (YoY)	41.2%	N/A
Forward Rev Growth	10.9%	157.2%
Profitability
Gross Margin (TTM)	82.4%	0.0%
Operating Margin (TTM)	35.6%	0.0%
EBITDA Margin (TTM)	63.7%	0.0%
Net Margin (TTM)	24.9%	0.0%
FCF Margin (TTM)	31.2%	N/A
Net Income (TTM)	$414M	$-1.06B
FCF (TTM)	$518M	$-921M
EPS (TTM)	$3.41	-$7.37
ROE (TTM)	180.6%	-3757.0%
ROA (TTM)	16.6%	-3362.0%
ROIC (TTM)	18.7%	-3757.0%
Financial Health
Cash	$163M	$183M
Debt	$2.15B	$0
Net Cash/Debt	$-1.98B	$183M
Current Ratio (TTM)	2.71x	5.72x
Quick Ratio (TTM)	1.99x	5.48x
Debt/Equity (TTM)	14.95x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.94	1.31
52W Performance	69.4%	75.2%
YTD Performance	57.0%	53.6%
% from 52W High	-5.5%	-21.3%
% from 52W Low	80.3%	79.0%
Efficiency & Yields
Asset Turnover (TTM)	0.67x	0.00x
FCF Yield (TTM)	4.0%	-8.9%
Earnings Yield (TTM)	3.2%	-10.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	72.3	0.0
EV/GP/RG	0.44	N/A
Ticker research	View HALO research	View PCVX research